Home Featured Page 226

Featured

Latest

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Delix Therapeutics Expands Executive Leadership Team

Horizons ETFs Rebalances World’s First Psychedelics ETF

MYND Life Sciences Provides Corporate Update

Clerkenwell Signs First Multi-million Pound Contract with International Psychedelic Bio-tech Company

Real World Research in Psychedelic Science

PT252 – Joel Lambert – Ibogaine, 5-MeO-DMT, and The Warrior Tradition

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create...

Psyched Wellness Receives Positive Results from Its 14-Day Oral Toxicity Preclinical...

Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental...

COMPASS Pathways joins forces with King’s College London and South London...

1...225226227...292 Page 226 of 292

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

Dylan Beynon – Mindbloom – At Home Ketamine

Beckley’s 5-MeO-DMT Shows Rapid, Durable Antidepressant Effects in Phase 2b Study

Delix Therapeutics Expands Executive Leadership Team

Horizons ETFs Rebalances World’s First Psychedelics ETF

MYND Life Sciences Provides Corporate Update

Clerkenwell Signs First Multi-million Pound Contract with International Psychedelic Bio-tech Company

Real World Research in Psychedelic Science

PT252 – Joel Lambert – Ibogaine, 5-MeO-DMT, and The Warrior Tradition

Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create...

Psyched Wellness Receives Positive Results from Its 14-Day Oral Toxicity Preclinical...

Cybin Enters into Collaboration Agreement with Greenbrook TMS to Establish Mental...

COMPASS Pathways joins forces with King’s College London and South London...

EDITOR PICKS

Oregon Psilocybin Services Tracker: Q1 2025

Reconstructing Meaning: Chris Timmermann on the Neurophenomenology of Psychedelics

Mattha Busby: Power, Pleasure, and the Psychedelic Movement’s Reckoning

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY